Hypertension in pregnancy is defined as a systolic blood pressure of ≥140 mmHg or a diastolic blood pressure of ≥90 mmHg, or both, based on at least 2 measurements ≥4 hours apart.
Diagnosis of severe hypertension is made when blood pressure is ≥160/110 mmHg.
Measurement should be repeated after 15 minutes for confirmation of severe hypertension.
Pregnant women with elevated blood pressure (BP) levels below the diagnostic criteria of hypertensive disorders of pregnancy (HDP) at 28 and 34 weeks of gestation are at high risk of developing stage 1 hypertension 5 years later, a study has found.
Women with hypertensive disorders of pregnancy, especially pre-eclampsia, are at heightened risk of developing cardiovascular disorder and chronic hypertension, with the risk becoming apparent soon after pregnancy, a study has found.
Exposure to higher levels of criteria air pollutants carries an increased risk of gestational hypertension but a lower risk of pre-eclampsia, whereas greater exposure to volatile organic compounds poses a heightened risk of pre-eclampsia and has no effect on gestational hypertension, according to a recent study.
A recent study suggests that nocturnal hypertension at high-risk mid-pregnancy is common and strongly predicts pre-eclampsia/eclampsia (PEEC). Such risk was two times higher in women not taking acetylsalicylic acid (ASA).
Rapid blood pressure (BP) elevations during the second trimester of pregnancy may pose an increased risk of delivering a low birthweight (LBW) infant, as well as contribute to impaired maternal liver, kidney and coagulation functions, according to a study presented at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US.
Women with pre-eclampsia or gestational hypertension during their first pregnancy had an increased risk of developing chronic hypertension, type 2 diabetes (T2D), and hypercholesterolaemia than those who were normotensive during pregnancy, according to a study. The risk persisted for several decades later, signalling these hypertensive disorders of pregnancy (HDP) as red flags for cardiovascular (CV) health for life.
Treatment with finerenone led to significantly reduced risk of cardiovascular (CV) events in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), regardless of their CV disease (CVD) history, according to the FIDELIO-DKD* trial presented at AHA 2020.